3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neuroblastoma
3
Leukemia
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Thrombocytopenia
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Blast Crisis
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Refractory
1
Interventions
Temozolomide
3
Filgrastim
2
Drug Therapy
2
talazoparib
1
sargramostim
1
pembrolizumab
1
oblimersen
1
irinotecan sucrosofate
1
etoposide phosphate
1
entrectinib
1
atezolizumab
1
X-Rays
1
Vincristine
1
Specimen Handling
1
Radiotherapy
1
Radiosurgery
1
Proteasome Inhibitors
1
Platinum
1
Phantoms, Imaging
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Monatide (IMS 3015)
1
Microarray Analysis
1
Lenalidomide
1
Isotretinoin
1
Irinotecan
1
Immunomodulating Agents
1
Immunohistochemistry
1
Ifosfamide
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Wilms Tumor
×
Isotretinoin
×
Clear all
NCT05384821
2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2
Recruiting
28 enrolled